PharmiWeb Today Story
- Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung cancer (NSCLC)1
- This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy2
- The National Comprehensive Cancer Network® (NCCN®) Guidelines recommend routine testing for ALK, EGFR and PD-L1 biomarkers in people with early-stage NSCLC to inform adjuvant therapy selection
Basel, 19 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Alecensa® (alectinib) for adjuvant treatment following tumour resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumours ≥ 4 cm or node positive), as detected by an FDA-approved test. Alecensa is now the first and only ALK inhibitor approved for people with ALK-positive early-stage NSCLC who have undergone surgery to remove their tumour.
“With an unprecedented 76% reduction in the risk of disease recurrence or death versus chemotherapy, Alecensa significantly improves upon the standard of care for people with early-stage ALK-positive lung cancer,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “At Roche, our goal is to give patients the best chance of cure by bringing effective, targeted treatments to early-stage disease befor…
Read More...Articles
What Does a Clinical SAS Programmer Do?
16-Apr-2024
The Evolution of Clinical Data Management
10-Apr-2024
9 Clinical Data Management Career Paths
08-Apr-2024
Featured Events
-
Pharmaceutical Manufacturing & Packaging Congress…
28-Jun-2021 - 29-Jun-2021 -
6th CAR-TCR Summit
30-Aug-2021 - 02-Sep-2021 -
1st International Conference “WE! are the Clinical…
18-Sep-2021 - 18-Sep-2021 -
Pharmaceutical Manufacturing and Packaging Congres…
20-Jun-2022 - 21-Jun-2022 -
How to impact, influence & inspire
07-Feb-2023 - 21-Feb-2023 -
Genomics and Precision Medicine Expo
23-May-2023 - 24-May-2023
News
-
Nutriband Inc. Announces $8.4M Private Placement
19-Apr-2024 -
Herbal Supplements Market Value to Hit USD 94.3 bi…
19-Apr-2024 -
Vita 34 closes 2023 with significantly better resu…
19-Apr-2024 -
Insect Protein Market Size, To Witness Promising G…
19-Apr-2024 -
Healthy Snack Market Sales to Top USD 142.6 Billio…
19-Apr-2024 -
Negative Pressure Wound Therapy Market Expected to…
19-Apr-2024